Home › Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA (Ceftolozane and Tazobactam)
 

Keywords :   


Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA (Ceftolozane and Tazobactam)

2015-07-27 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA (ceftolozane and tazobactam) for the treatment of the following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: positive opinion receives antibiotic

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07'Floodgates open' for legal action against water firms
03.07Atlantic Tropical Weather Outlook
03.07Eastern North Pacific Tropical Weather Outlook
More »